Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00267267
Other study ID # A5091035
Secondary ID
Status Terminated
Phase Phase 3
First received December 19, 2005
Last updated December 6, 2007
Start date January 2006
Est. completion date January 2007

Study information

Verified date December 2006
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

Cholesterol levels will be measured over six weeks in subjects being treated with two different kinds of combination cholesterol medications to see how the different treatments compare to one another.


Description:

For additional information please call: 1-800-718-1021


Recruitment information / eligibility

Status Terminated
Enrollment 1784
Est. completion date January 2007
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Specific LDL-C levels based on CHD risk after a six-week washout period.

Exclusion Criteria:

- Women who are pregnant or lactating, or planning to become pregnant.

- Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors.

- Subjects requiring systemic steroids

- Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
torcetrapib/atorvastatin

ezetimibe/simvastatin


Locations

Country Name City State
United States Pfizer Investigational Site Anaheim California
United States Pfizer Investigational Site Anderson South Carolina
United States Pfizer Investigational Site Arlington Texas
United States Pfizer Investigational Site Atlanta Georgia
United States Pfizer Investigational Site Atlanta Georgia
United States Pfizer Investigational Site Atlanta Georgia
United States Pfizer Investigational Site Atlantis Florida
United States Pfizer Investigational Site Aurora Illinois
United States Pfizer Investigational Site Ayer Massachusetts
United States Pfizer Investigational Site Beaver Pennsylvania
United States Pfizer Investigational Site Bensalem Pennsylvania
United States Pfizer Investigational Site Birmingham Alabama
United States Pfizer Investigational Site Birmingham Alabama
United States Pfizer Investigational Site Bloomfield Hills Michigan
United States Pfizer Investigational Site Boca Raton Florida
United States Pfizer Investigational Site Boston Massachusetts
United States Pfizer Investigational Site Boston Massachusetts
United States Pfizer Investigational Site Bountiful Utah
United States Pfizer Investigational Site Bristol Tennessee
United States Pfizer Investigational Site Brooklyn Center Minnesota
United States Pfizer Investigational Site Cary North Carolina
United States Pfizer Investigational Site Chandler Arizona
United States Pfizer Investigational Site Charlotte North Carolina
United States Pfizer Investigational Site Chattanooga Tennessee
United States Pfizer Investigational Site Chicago Illinois
United States Pfizer Investigational Site Cincinnati Ohio
United States Pfizer Investigational Site Cleveland Ohio
United States Pfizer Investigational Site Columbia Missouri
United States Pfizer Investigational Site Columbia Maryland
United States Pfizer Investigational Site Cooperstown New York
United States Pfizer Investigational Site Daytona Beach Florida
United States Pfizer Investigational Site DeFuniak Springs Florida
United States Pfizer Investigational Site Des Moines Iowa
United States Pfizer Investigational Site Destin Florida
United States Pfizer Investigational Site Doylestown Pennsylvania
United States Pfizer Investigational Site Edgewood Kentucky
United States Pfizer Investigational Site Edina Minnesota
United States Pfizer Investigational Site Endwell New York
United States Pfizer Investigational Site Erlanger Kentucky
United States Pfizer Investigational Site Escondido California
United States Pfizer Investigational Site Evansville Indiana
United States Pfizer Investigational Site Evansville Indiana
United States Pfizer Investigational Site Evansville Indiana
United States Pfizer Investigational Site Fairview Park Ohio
United States Pfizer Investigational Site Fresno California
United States Pfizer Investigational Site Germantown Tennessee
United States Pfizer Investigational Site Golden Colorado
United States Pfizer Investigational Site Grand Rapids Michigan
United States Pfizer Investigational Site Harleysville Pennsylvania
United States Pfizer Investigational Site Honolulu Hawaii
United States Pfizer Investigational Site Houston Texas
United States Pfizer Investigational Site Houston Texas
United States Pfizer Investigational Site Huntersville North Carolina
United States Pfizer Investigational Site Jefferson City Missouri
United States Pfizer Investigational Site Johnson City Tennessee
United States Pfizer Investigational Site Jonesboro Arkansas
United States Pfizer Investigational Site Lakeland Florida
United States Pfizer Investigational Site Lancaster Pennsylvania
United States Pfizer Investigational Site Las Vegas Nevada
United States Pfizer Investigational Site Las Vegas Nevada
United States Pfizer Investigational Site Lewiston New York
United States Pfizer Investigational Site Lincoln Rhode Island
United States Pfizer Investigational Site Los Altos California
United States Pfizer Investigational Site Los Angeles California
United States Pfizer Investigational Site Louisville Kentucky
United States Pfizer Investigational Site Manchester Missouri
United States Pfizer Investigational Site Manlius New York
United States Pfizer Investigational Site Memphis Tennessee
United States Pfizer Investigational Site Memphis Tennessee
United States Pfizer Investigational Site Memphis Tennessee
United States Pfizer Investigational Site Memphis Tennessee
United States Pfizer Investigational Site Mesa Arizona
United States Pfizer Investigational Site Miami Florida
United States Pfizer Investigational Site Miami Florida
United States Pfizer Investigational Site Miami Florida
United States Pfizer Investigational Site Milford Massachusetts
United States Pfizer Investigational Site Monroe North Carolina
United States Pfizer Investigational Site Mount Pleasant South Carolina
United States Pfizer Investigational Site New Haven Connecticut
United States Pfizer Investigational Site Newark Delaware
United States Pfizer Investigational Site Newport News Virginia
United States Pfizer Investigational Site Newton Kansas
United States Pfizer Investigational Site Norfolk Virginia
United States Pfizer Investigational Site Omaha Nebraska
United States Pfizer Investigational Site Omaha Nebraska
United States Pfizer Investigational Site Omaha Nebraska
United States Pfizer Investigational Site Orlando Florida
United States Pfizer Investigational Site Overland Park Kansas
United States Pfizer Investigational Site Palm Springs California
United States Pfizer Investigational Site Paramount California
United States Pfizer Investigational Site Pensacola Florida
United States Pfizer Investigational Site Pittsburgh Pennsylvania
United States Pfizer Investigational Site Pittsburgh Pennsylvania
United States Pfizer Investigational Site Pratt Kansas
United States Pfizer Investigational Site Providence Rhode Island
United States Pfizer Investigational Site Raleigh North Carolina
United States Pfizer Investigational Site Renton Washington
United States Pfizer Investigational Site Rochester New York
United States Pfizer Investigational Site Rochester New York
United States Pfizer Investigational Site Rockford Illinois
United States Pfizer Investigational Site Salt Lake City Utah
United States Pfizer Investigational Site San Antonio Texas
United States Pfizer Investigational Site San Antonio Texas
United States Pfizer Investigational Site San Diego California
United States Pfizer Investigational Site Santa Rose California
United States Pfizer Investigational Site Sayre Pennsylvania
United States Pfizer Investigational Site Selmer Tennessee
United States Pfizer Investigational Site Simpsonville South Carolina
United States Pfizer Investigational Site Spokane Washington
United States Pfizer Investigational Site Springfield Illinois
United States Pfizer Investigational Site Springfield Missouri
United States Pfizer Investigational Site Springfield Missouri
United States Pfizer Investigational Site St. Cloud Minnesota
United States Pfizer Investigational Site Syracuse New York
United States Pfizer Investigational Site Topeka Kansas
United States Pfizer Investigational Site Troy Michigan
United States Pfizer Investigational Site Walnut Creek California
United States Pfizer Investigational Site Washington District of Columbia
United States Pfizer Investigational Site West Seneca New York
United States Pfizer Investigational Site Westlake Village California
United States Pfizer Investigational Site Wilmington North Carolina
United States Pfizer Investigational Site Winston-Salem North Carolina
United States Pfizer Investigational Site Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percent change in LDL-C and HDL-C from baseline, after six weeks of treatment.
Secondary Changes in other lipid parameters and other biomarkers.
See also
  Status Clinical Trial Phase
Completed NCT00001154 - Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
Not yet recruiting NCT06405880 - Pharmacist Case Finding and Intervention for Vascular Prevention Trial N/A
Recruiting NCT02837367 - Use of Nutrigenomic Models for the Personalized Treatment With Medical Foods in Obese People N/A
Active, not recruiting NCT02600338 - Meta-analyses of the Effect of Legumes on Blood Pressure N/A
Active, not recruiting NCT02223793 - Vascular Lifestyle-Intervention and Screening in Pharmacy N/A
Completed NCT02163044 - The Hellenic Postprandial Lipemia Study (HPLS)
Recruiting NCT01972113 - Vitamin K and Glucose Metabolism in Children at Risk for Diabetes (Vita-K 'n' Kids Study) N/A
Recruiting NCT01705873 - Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen N/A
Completed NCT01764295 - Clinical Study for Patients With Hypertension Associated With Dyslipidemia Phase 3
Terminated NCT01414166 - Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108) Phase 3
Completed NCT01990391 - Brazil Nut Consumption in Microvascular Endothelial Function, Oxidative Stress and Metabolic Abnormalities N/A
Completed NCT01531062 - Effect of Nigella Sativa on Lipid Profiles in Elderly Phase 2
Recruiting NCT01670968 - HIV Reverse Cholesterol Transport Study
Completed NCT00977288 - A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029) Phase 2
Withdrawn NCT00664287 - Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082) Phase 3
Completed NCT00768274 - Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol Phase 1/Phase 2
Completed NCT01285544 - The Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia Phase 4
Completed NCT00300430 - Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia. Phase 3
Completed NCT01483235 - Reduced Cardiac Rehabilitation Program N/A
Terminated NCT00816829 - Effect of Fenofibrate on Sleep Apnea Syndrome Phase 2